CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Global assessment of leukemia care quality: insights from the quality of care index (QCI) from 1990 to 2021

Pan, Y., Liu, Q., Zhang, N., Peng, S., Li, X., & Zhou, F. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102996 · Cited by 38

Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications

Rezazadeh‐Gavgani, E., Majidazar, R., Lotfinejad, P., Kazemi, T., & Shamekh, A. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70196 · Cited by 46

Rational design of lipid nanoparticles for enabling gene therapies

Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 45

Advances in the regulation of macrophage polarization by the tumor microenvironment

Peng, M., Zhu, Y., Hu, Y., Wen, J., & Huang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-03258-9 · Cited by 44

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches

Uccello, M., Boussios, S., Samartzis, E. P., & Moschetta, M. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.04.15 · Cited by 38

Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector

Chen, H., Fan, Y., Hao, X., Yang, C., Peng, Y., Guo, R., Shi, X., & Cao, X. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00678e · Cited by 38

The Anticancer Potential of Apigenin Via Immunoregulation

Xu, L., Zaky, M. Y., Yousuf, W., Ullah, A., Abdelbaset, G. R., Zhang, Y., Ahmed, O. M., Liu, S., & Liu, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200713171137 · Cited by 40

Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Mančíková, V., & Šmída, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115536 · Cited by 39

Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy

Bohineust, A., Tourret, M., Lew‐Derivry, L., & Caillat‐Zucman, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.07.003 · Cited by 41

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Stirling, E. R., Bronson, S. M., Mackert, J. D., Cook, K. L., Triozzi, P. L., & Soto‐Pantoja, D. R. (2022) · Cells · doi:10.3390/cells11010179 · Cited by 39

Polymersomes as a potential platform for cancer immunotherapy

Scheerstra, J. F., Wauters, A. C., Tel, J., Abdelmohsen, L. K. E. A., & van Hest, J. C. M. (2021) · Materials Today Advances · doi:10.1016/j.mtadv.2021.100203 · Cited by 41

Macroencapsulation Devices for Cell Therapy

Liu, W., Wang, Y., Wang, J., Lanier, O. L., Wechsler, M. E., Peppas, N. A., & Gu, Z. (2022) · Engineering · doi:10.1016/j.eng.2021.10.021 · Cited by 38

Structure–Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold

Matikonda, S. S., McLaughlin, R., Shrestha, P., Lipshultz, C., & Schnermann, M. J. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00177 · Cited by 38

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37

Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer

Lin, C.-W., Wang, Y.-J., Lai, T.-Y., Hsu, T.-L., Han, S.-Y., Wu, H., Shen, C., Dang, V., Chen, M. W., Chen, L.-B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114774118 · Cited by 36

Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity

Qin, Y., Lu, F., Lyu, K., Chang, A. E., & Li, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.881427 · Cited by 40

Natural killer cells in the central nervous system

Ning, Z., Liu, Y., Guo, D., Lin, W., & Tang, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01324-9 · Cited by 41

Tracing the development of CAR-T cell design: from concept to next-generation platforms

Alsaieedi, A., & Zaher, K. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615212 · Cited by 49

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma

Ren, L., Leisegang, M., Deng, B., Matsuda, T., Kiyotani, K., Kato, T., Harada, M., Park, J., Saloura, V., Seiwert, T. Y., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568813 · Cited by 36

Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches

Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 38

Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy

Hope, H. C., & Salmond, R. J. (2019) · European Journal of Immunology · doi:10.1002/eji.201848058 · Cited by 38

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

Klesmith, J. R., Su, L., Wu, L., Schrack, I. A., Dufort, F. J., Birt, A., Ambrose, C. M., Hackel, B. J., Lobb, R. R., & Rennert, P. D. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00418 · Cited by 37

Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms

Song, W., Das, M., & Chen, X. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.011 · Cited by 38

Targeting T Cell Activation in Immuno-Oncology

Saibil, S. D., & Ohashi, P. S. (2020) · Current Oncology · doi:10.3747/co.27.5285 · Cited by 39

MR1-Restricted T Cells Are Unprecedented Cancer Fighters

Vacchini, A., Chancellor, A., Spagnuolo, J., Mori, L., & Libero, G. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00751 · Cited by 34

Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy

Tian, R., Ke, C., Rao, L., Lau, J., & Chen, X. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.009 · Cited by 37

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting

Grote, S., Mittelstaet, J., Baden, C., Chan, K. C.-H., Seitz, C. M., Schlegel, P., Kaiser, A., Handgretinger, R., & Schleicher, S. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1825177 · Cited by 37

Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain

Ma, S., Wang, X., Hu, Y., Lv, J., Liu, C., Liao, K., Guo, X., Wang, D., Lin, Y., & Rong, Z. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa779 · Cited by 36

Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture

Ponterio, E., Maria, R. D., & Haas, T. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565631 · Cited by 37

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

Alijaj, N., Moutel, S., Gouveia, Z. L., Gray, M., Roveri, M., Dzhumashev, D., Weber, F., Meier, G., Luciani, P., Rössler, J. K., et al. (2020) · Cancers · doi:10.3390/cancers12113313 · Cited by 36

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma

Veigas, F., Mahmoud, Y. D., Merlo, J. P., Rinflerch, A., Rabinovich, G. A., & Girotti, M. R. (2021) · Cancers · doi:10.3390/cancers13051018 · Cited by 41

Emerging glyco‐based strategies to steer immune responses

Anderluh, M., Berti, F., Bzducha‐Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik-Popińska, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., et al. (2021) · FEBS Journal · doi:10.1111/febs.15830 · Cited by 38

Donor T cells for CAR T cell therapy

Tang, T. C. Y., Xu, N., Nordon, R. E., Haber, M., Micklethwaite, K. P., & Dolnikov, A. (2022) · Biomarker Research · doi:10.1186/s40364-022-00359-3 · Cited by 43

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

Hoeck, J. V., Braeckmans, K., Smedt, S. C. D., & Raemdonck, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121510 · Cited by 37

Clinical and Translational Advances in Glioma Immunotherapy

Bunse, L., Bunse, T., Krämer, C., Chih, Y., & Platten, M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01313-9 · Cited by 40

Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide

Niu, B., Appleby, T. C., Wang, R., Morar, M., Voight, J., Villaseñor, A. G., Clancy, S., Wise, S. J., Belzile, J.-P., Papalia, G. A., et al. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00822 · Cited by 37

A Systematic Review of Clinical Trials on the Efficacy and Safety of CRLX101 Cyclodextrin-Based Nanomedicine for Cancer Treatment

Serrano‐Martínez, A., Victoria‐Montesinos, D., García‐Muñoz, A. M., Hernández-Sánchez, P., Lucas-Abellán, C., & González-Louzao, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071824 · Cited by 36

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells

Mensurado, S., Condeço, C., Sánchez‐Martínez, D., Shirley, S., Coelho, R. M. L., Tirado, N., Vinyoles, M., Blanco-Domínguez, R., Barros, L., Galvão, B., et al. (2024) · Blood · doi:10.1182/blood.2023022992 · Cited by 38

CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects

Choudhery, M. S., Arif, T., Mahmood, R., & Harris, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113202 · Cited by 40

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins

Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 38

Comprehensive landscape of cell death mechanisms: from molecular cross-talk to therapeutic innovation in oncology

Ke, Q., Mu, Y., Hu, Y., Li, J., & Liu, J. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1611055 · Cited by 43

Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment

Li, M., Liu, Z., & Wang, X. (2018) · Journal of Oncology · doi:10.1155/2018/3979527 · Cited by 37

Immunotherapy in Ovarian Cancer

Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies

Pölönen, P., Mehtonen, J., Lin, J., Liuksiala, T., Häyrynen, S., Teppo, S., Mäkinen, A., Kumar, A., Malani, D., Pohjolainen, V., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2970 · Cited by 36

Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy

Bai, Y., Wang, Y., Zhang, X., Fu, J., Xing, X., Wang, C., Gao, L., Liu, Y., & Shi, L. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118636 · Cited by 36

A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells in Vivo

Pascoal, S., Salzer, B., Scheuringer, E., Wenninger-Weinzierl, A., Sturtzel, C., Holter, W., Taschner‐Mandl, S., Lehner, M., & Distel, M. (2020) · Cancers · doi:10.3390/cancers12030567 · Cited by 37

Prognostic Implications of Immune-Related Genes’ (IRGs) Signature Models in Cervical Cancer and Endometrial Cancer

Ding, H., Fan, G., Yi, Y., Zhang, W., Xiong, X., & Mahgoub, O. K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00725 · Cited by 36

Preclinical development of CD126 CAR-T cells with broad antitumor activity

Mishra, A. K., Kemler, I., & Dingli, D. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00405-z · Cited by 35

CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing

Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.013 · Cited by 38

Is immunotherapy in the future of therapeutic management of sarcomas?

Clemente, O., Ottaiano, A., Lorenzo, G. D., Bracigliano, A., Lamia, S., Cannella, L., Pizzolorusso, A., Marzo, M. D., Santorsola, M., Chiara, A. D., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02829-y · Cited by 38

One-Time Optimization of Advanced T Cell Culture Media Using a Machine Learning Pipeline

Grzesik, P., & Warth, S. C. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.614324 · Cited by 36

Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy

Yang, L., Li, F., Cao, Y., Liu, Q., Jing, G., Niu, J., Sun, F., Qian, Y., Wang, S., & Li, A. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01073-2 · Cited by 36

The role of neoantigens in tumor immunotherapy

Shang, S., Zhao, Y., Qian, K., Qin, Y., Zhang, X., Li, T., Shan, L., Wei, M., Xi, J., & Tang, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113118 · Cited by 37

Targeting glycans for CAR therapy: The advent of sweet CARs

Raglow, Z., McKenna, M. K., Bonifant, C. L., Wang, W., di Magliano, M. P., Stadlmann, J., Penninger, J. M., Cummings, R. D., Brenner, M. K., & Markovitz, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.006 · Cited by 36

Current advances of CRISPR-Cas technology in cell therapy

Qiu, H.-Y., Ji, R.-J., & Zhang, Y. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100067 · Cited by 38

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38

RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review

Faruqui, T., Khan, M. S., Akhter, Y., Khan, S., Rafi, Z., Saeed, M., Han, I., Choi, E. H., & Yadav, D. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010266 · Cited by 36

Innovative hydrogel-based delivery systems for immunotherapy: A review of pre-clinical progress

Mamidi, N., Poellmann, M. J., Javius-Jones, K., Nam, K., & Hong, S. (2024) · Nano Research · doi:10.1007/s12274-024-6980-z · Cited by 39

Build-a-bug workshop: Using microbial-host interactions and synthetic biology tools to create cancer therapies

Raman, V., Deshpande, C. P., Khanduja, S., Howell, L. M., Dessel, N. V., & Forbes, N. S. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.09.006 · Cited by 37

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models

Timpanaro, A., Piccand, C., Dzhumashev, D., Anton-Joseph, S., Robbi, A., Moser, J. J., Rössler, J. K., & Bernasconi, M. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02838-3 · Cited by 36

Current status and future challenges of CAR-T cell therapy for osteosarcoma

Li, S., Zhang, H., & Shang, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290762 · Cited by 37

NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer

Li, J., Hu, H., Lian, H., Yang, S., Liu, M., He, J., Cao, B., Chen, D. S., Hu, Y., Zhi, C., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88539 · Cited by 39

TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens

Huang, D., Li, Y., Rui, W., Sun, K., Zhou, Z., Lv, X., Li, Y., Chen, J., Zhou, J., Liu, V., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114949 · Cited by 36

Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions

Rafii, S., Mukherji, D., Komaranchath, A. S., Khalil, C., Iqbal, F., Abdelwahab, S. İ., Abyad, A. M., Abuhelwa, A. Y., Gandikota, L., & Al-Shamsi, H. O. (2025) · Cancers · doi:10.3390/cancers17172898 · Cited by 41

Immunotherapy in pancreatic cancer: New hope or mission impossible?

Jiang, J., Zhou, H., Ni, C., Hu, X., Mou, Y., Huang, D., & Yang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.045 · Cited by 37

Acceptability of Cell and Gene Therapy for Curing HIV Infection Among People Living with HIV in the Northwestern United States: A Qualitative Study

Dubé, K., Simoni, J. M., Louella, M., Sylla, L. N., Mohamed, Z. H., Patel, H., Luter, S., & Collier, A. C. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0021 · Cited by 35

Novel immunotherapeutic approaches for hepatocellular carcinoma treatment

Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 36

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer

Simon, B., Harrer, D. C., Schuler‐Thurner, B., Schuler, G., & Uslu, U. (2019) · Cancers · doi:10.3390/cancers11050696 · Cited by 36

Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments

Brandi, G., & Frega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112699 · Cited by 36

Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype

Canestrari, E., Steidinger, H. R., McSwain, B., Charlebois, S., & Dann, C. T. (2019) · Journal of Immunology Research · doi:10.1155/2019/3616120 · Cited by 36

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives

Zeng, Q., Zhou, Y., & Schwarz, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02216 · Cited by 36

Anticalin® proteins: from bench to bedside

Deuschle, F., Ilyukhina, E., & Skerra, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1839046 · Cited by 35

CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

Ugolini, A., & Nuti, M. (2021) · Cancers · doi:10.3390/cancers13030456 · Cited by 36

Supramolecular co-assembly of self-adjuvanting nanofibrious peptide hydrogel enhances cancer vaccination by activating MyD88-dependent NF-κB signaling pathway without inflammation

Su, Q., Song, H., Huang, P., Zhang, C., Yang, J., Kong, D., & Wang, W. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.041 · Cited by 37

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy

Kittel-Boselli, E., Soto, K. E. G., Loureiro, L. R., Hoffmann, A., Bergmann, R., Arndt, C., Koristka, S., Mitwasi, N., Kegler, A., Bartsch, T., et al. (2021) · Cancers · doi:10.3390/cancers13194785 · Cited by 35

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function

Wang, H., Chen, H., Liu, S., Zhang, J., Lu, H., Somasundaram, R., Choi, R., Zhang, G., Ou, L., Scholler, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003339 · Cited by 34

Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors

Mandriani, B., Pellè, E., Mannavola, F., Palazzo, A. J., Marsano, R. M., Ingravallo, G., Cazzato, G., Ramello, M. C., Porta, C., Strosberg, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004854 · Cited by 41

In vivo gene immunotherapy for cancer

Mai, D., June, C. H., & Sheppard, N. C. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3603 · Cited by 35

Perivascular stromal cells: Directors of tissue immune niches

Sbierski‐Kind, J., Mroz, N. M., & Molofsky, A. B. (2021) · Immunological Reviews · doi:10.1111/imr.12984 · Cited by 35

Nanoengineered coordination polymers boost cancer immunotherapy

Li, X., Yamazaki, T., Ebara, M., Shirahata, N., & Hanagata, N. (2023) · Materials Today · doi:10.1016/j.mattod.2023.06.001 · Cited by 34

Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy

Shi, Y., Shi, D., Chi, J., Cui, D., Tang, X., Lin, Y., Wang, S., Li, Z., Jin, H., & Zhai, B. (2023) · 癌症：英文版 · doi:10.1002/cac2.12472 · Cited by 34

Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities

Dominguez-Cejudo, M. A., Gil-Torralvo, A., Solís, M. C., Molina‐Pinelo, S., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316771 · Cited by 42

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells

Botta, G. P., Chao, J., Ma, H., Hahn, M. G., Sierra, G., Jia, J., Hendrix, A. Y., Fong, J. N., Ween, A., Vu, P., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007927 · Cited by 34

Novel and potential future therapeutic options in systemic autoimmune diseases

Balogh, L., Oláh, K., Sánta, S., Majerhoffer, N., & Németh, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1249500 · Cited by 36

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies

Wu, J., Bloch, N., Chang, A. Y., Bhavsar, R., Wang, Q., Crawford, A., DiLillo, D. J., Vazzana, K., Mohrs, K., Dudgeon, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101747 · Cited by 36

Natural killer cell–based immunotherapy for cancer

Ma, S., Yu, J., & Caligiuri, M. A. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf036 · Cited by 40

The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer

Kannan, K., Srinivasan, A., Kannan, A., & Ali, N. (2025) · Cancers · doi:10.3390/cancers17172938 · Cited by 44

Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases

Chan, M. W. Y., & Viswanathan, S. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.02.002 · Cited by 34

Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells

Sawasdee, N., Thepmalee, C., Sujjitjoon, J., Yongpitakwattana, P., Junking, M., Poungvarin, N., Yenchitsomanus, P., & Panya, A. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106006 · Cited by 34

Systemic Regulation of Cancer Development by Neuro-Endocrine-Immune Signaling Network at Multiple Levels

Jiang, S., Zhang, X.-X., Hu, L.-P., Wang, X., Li, Q., Zhang, X., Li, J., Gu, J., & Zhang, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.586757 · Cited by 34

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

Kast, F., Klein, C., Umaña, P., Gros, A., & Gasser, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1869389 · Cited by 34

The burgeoning role of MR1-restricted T-cells in infection, cancer and autoimmune disease

Crowther, M. D., & Sewell, A. K. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.12.002 · Cited by 36

CAR T cell therapy in solid tumors: a short review

Umut, Ö., Gottschlich, A., Endres, S., & Kobold, S. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00703-7 · Cited by 37

Cell therapies in ovarian cancer

Sarivalasis, A., Morotti, M., Mulvey, A., Imbimbo, M., & Coukos, G. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211008399 · Cited by 36

Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer

Zhang, F., Wang, X., Bai, Y., Hu, H., Yang, Y., Wang, J., Tang, Y., Ma, H., Feng, D., Li, D., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.670384 · Cited by 34

Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells

Han, B., Song, Y., Park, J., & Doh, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.049 · Cited by 33

Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?

Gatto, L., Nunno, V. D., Franceschi, E., Tosoni, A., Bartolini, S., & Brandes, A. A. (2022) · Drugs · doi:10.1007/s40265-022-01702-6 · Cited by 35

Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications

Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022) · Immunology · doi:10.1111/imm.13573 · Cited by 38

Recent progress in cancer immunotherapy: Overview of current status and challenges

Darvishi, M., Tosan, F., Nakhaei, P., Manjili, D. A., Kharkouei, S. A., Alizadeh, A. M., Ilkhani, S., Khalafi, F., Zadeh, F. A., & Shafagh, S.-G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154241 · Cited by 35

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01